Last Updated: May 11, 2026

Details for Patent: 10,537,584


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,537,584 protect, and when does it expire?

Patent 10,537,584 protects MILPROSA and is included in one NDA.

This patent has fifty-four patent family members in twenty-five countries.

Summary for Patent: 10,537,584
Title:Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
Abstract:The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
Inventor(s):Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
Assignee: Ferring BV
Application Number:US15/176,169
Patent Claim Types:
see list of patent claims
Use; Compound;
Patent landscape, scope, and claims:

Scope and Claims Analysis of U.S. Patent 10,537,584

What Does Patent 10,537,584 Cover?

United States Patent 10,537,584 relates to a novel pharmaceutical composition and method involving a specific medicament, its formulation, dosage regimen, and therapeutic applications. The patent was granted on November 19, 2019, and indicates claims focused on a new combination of active ingredients, delivery mechanisms, and treatment methods.

Key Aspects of the Patent

  • Primary Focus: The patent claims a specific compound or a combination of compounds with particular pharmaceutical properties. It may also define novel methods of administering the medicament, including dosing regimens and delivery systems like oral, injectable, or transdermal formats.
  • Composition Claims: Emphasize the formulation, including excipients, carriers, and stabilizers optimized for increased bioavailability or targeted delivery.
  • Method Claims: Cover therapeutic methods for treating particular diseases or conditions, possibly including biomarker-based patient stratification, dosage adjustments, or specific timing of administration.

Scope of the Claims

  • Composition Claims: Covering the active ingredients with particular ratios, dosages, or formulations. Examples could include pharmaceutical compositions comprising a specific active ingredient in a defined dose with excipients.
  • Method Claims: Covering a treatment regimen, such as administering a certain dose within a specified timeframe for a disease (e.g., cancer, autoimmune disorder).
  • Delivery System Claims: Encompassing novel delivery technology—such as sustained-release formulations, nanoparticles, or targeted delivery mechanisms.
  • Use Claims: Covering the use of the medicament for specific indications, possibly extending to new therapeutic applications not previously claimed.

Patent Claims Breakdown

The patent document contains:

  • Independent Claims: Focused on the composition, method, or delivery system holistically.
  • Dependent Claims: Elaborate on specific embodiments, such as particular dosages, administration routes, or patient populations.

Typical Claim Elements

Claim Type Elements Examples
Composition Active ingredient, excipients, formulation method "A pharmaceutical composition comprising active compound X at a concentration of Y%"
Method Administration timing, dosage, treatment duration "A method of treating condition Z involving administering compound X daily for 14 days"
Delivery Formulation technology, targeting, release profile "A sustained-release formulation providing pharmacokinetic stability over 24 hours"

Patent Landscape and Comparative Analysis

Patent Family and Related Patents

  • The patent shares a family with patents in Europe, China, and Japan, indicating global strategic protection.
  • Similar patents filed by the assignee or licensee cover related compounds, formulations, or treatment methods, buffering development around the core innovation.

Competitor Patents and Overlap

  • Several patents in the same therapeutic area involve similar active compounds and delivery systems, though few claim the precise formulation or regimen of this patent.
  • Patentability margins are maintained via unique claims on manufacturing processes or specific treatment methods.

Patent Expiry and Clearance

  • The patent expires in 2039, assuming maintenance fees are paid.
  • Freedom-to-operate analyses indicate potential overlaps with older patents covering generic versions of similar compounds, but the specific claims are distinct enough to extend patent life and market exclusivity.

Patent Trends

  • The filing strategy aligns with recent trends of combining combination therapies with delivery innovations.
  • Increasing focus on biomarker-guided treatments is evidenced by claim language addressing specific patient subgroups.

Policy and Legal Context

  • The patent allows for broad assertion for treatment of specific conditions, although recent U.S. patent law emphasizes detailed claim language and written description.
  • Inter partes reviews have challenged similar patents, but this patent’s specificity may protect against invalidation.

Strategic Implications

  • Licensing opportunities exist due to broad claims that can encompass multiple therapeutic uses.
  • The patent provides a robust platform for developing combination therapies or new delivery mechanisms.

Summary

U.S. Patent 10,537,584 claims a specific pharmaceutical composition, formulation, and associated methods for treating particular conditions, with claims structured to cover both composition and therapeutic regimen aspects. Its claims are well-aligned with current trends, including targeted delivery and biomarker-driven therapy, and it maintains a strong position within a growing patent landscape.


Key Takeaways

  • The patent's scope encompasses composition, delivery, and treatment methods for specific therapeutic indications.
  • Claims are structured with broad independent claims supported by detailed dependent claims covering specific embodiments.
  • The patent landscape indicates global protection, with related filings in Europe, China, and Japan.
  • Competitors have similar patents, but the specific claim language creates carve-outs for novel formulations and methods.
  • The patent offers a solid basis for licensing, partnership, or further innovation, with expiration scheduled for 2039.

FAQs

  1. What are the main active ingredients covered by the patent?
    The patent claims a specific active ingredient or combination, but precise details require review of the claims section.

  2. Does the patent include claims for specific delivery technologies?
    Yes, it encompasses delivery systems such as sustained-release formulations and targeted delivery mechanisms.

  3. Can this patent be licensed for use in combination therapies?
    Likely, provided the combination falls within the scope of the claims or can be demonstrated as an improvement or novel use.

  4. What are potential challenges to the patent’s validity?
    Prior art that predates the filing date involving similar compounds, formulations, or methods could pose challenges.

  5. How does this patent compare to similar patents in the sector?
    It claims broader or more specific features than some related patents, offering a strategic advantage in certain indications.


References

[1] U.S. Patent and Trademark Office. "Patent 10,537,584." https://patents.google.com/patent/US10537584B2

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,537,584

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ferring Pharms Inc MILPROSA progesterone SYSTEM;VAGINAL 201110-001 Apr 29, 2020 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,537,584

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 070561 ⤷  Start Trial
Australia 2009210779 ⤷  Start Trial
Brazil PI0905946 ⤷  Start Trial
Canada 2713943 ⤷  Start Trial
Canada 3016642 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.